---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical presentation - signs and symptoms. Topics: Symptom burden: often asymptomatic until advanced disease; Urinary findings: variable proteinuria, from subnephrotic to nephrotic range; Cardiovascular signs: hypertension; Kidney function: reduced eGFR at presentation; 3 further topics. 7 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Symptom burden: often asymptomatic until advanced disease

> “AMKD occurs in people of African ancestry, specifically of sub-Saharan origin, and is characterized by two APOL1 risk variants, proteinuria, rapid progression, early disease onset, lack of symptoms and other factors such as hypertension or a family history of kidney disease.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

> “In terms of the clinical presentation and course of APOL1 nephropathies, we do not know the extent to which the annual risk of incident kidney disease differs over the life course of these individuals; the extent to which APOL1 kidney disease first manifests as microalbuminuria, macroalbuminuria or reduced eGFR”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

<a id="topic-2.2.1.6-2"></a>

### Urinary findings: variable proteinuria, from subnephrotic to nephrotic range

> “The typical traits of APOL1 kidney disease include recent (<10,000 years) African ancestry, variable proteinuria, interstitial fibrosis, and reduced kidney function.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.1.6-3"></a>

### Cardiovascular signs: hypertension

> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

> “These variants, termed G1 and G2, are a frequent cause of kidney disease — termed APOL1 nephropathy — that typically manifests as focal segmental glomerulosclerosis and the clinical syndrome of hypertension and arterionephrosclerosis.”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

> “APOL1 risk alleles were associated under an additive model with systolic blood pressure (SBP) and age at diagnosis of hypertension, which was 2 to 5 years younger in the APOL1 variant allele homozygotes (Cox proportional hazards analysis, p value for combined meta-analysis [pcom] = 1.9 × 10−5).”
> “APOL1-associated estimated glomerular filtration rate decline was observed starting a decade later in life in the 30- to 39-year age range.”

Source: [Nadkarni et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5479565/)

> “Based on data from the United States, hypertension accelerates all forms of CKD progression,38 but it is not clear whether hypertension alone causes APOL1 kidney disease.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.6-4"></a>

### Kidney function: reduced eGFR at presentation

> “Among the 63% of patients with eGFR values recorded during the study period, the mean (SD) eGFR was 38 (29) mL/min/1.73 m2.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

> “Individuals with the APOL1 risk genotype tended to present at an older age and had significantly lower baseline eGFR, more segmental glomerulosclerosis and total glomerulosclerosis, and more tubular atrophy/interstitial fibrosis.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.1.6-5"></a>

### Age at onset: adolescence and early adulthood in APOL1-associated FSGS

> “As shown in Table 3, 70% of individuals with two APOL1 risk alleles experience onset of FSGS between the ages of 15 to 39 compared with 42% of carriers of 0 or 1 risk alleles (P = 0.0003, FET). Together these data support the idea that FSGS among APOL1 high-risk individuals is a distinct disease with earlier onset and tendency to present during the teenage years and early adulthood.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.1.6-6"></a>

### Acute presentation: acute kidney injury and nephrotic syndrome with collapsing glomerulopathy

> “All but one patient presented with AKI, 17 had nephrotic-range proteinuria, and six had nephrotic syndrome. Fourteen (61%) patients required dialysis at presentation. Among 17 patients genotyped, 16 (94%) were high-risk APOL1.”
> “Seventeen had nephrotic-range proteinuria when quantified, although only six had full nephrotic syndrome, largely due to the absence of edema.”
> “Seven had hematuria (defined as more than five red blood cells per high-power field; data available in n=21), and six had edema on physical examination.”

Source: [Kudose et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8806099/)

> “At biopsy day, mean serum creatinine was 6.5 mg/dl and mean urine protein-creatinine ratio was 11.5 g. Kidney biopsy specimens showed collapsing glomerulopathy, extensive foot process effacement, and focal/diffuse acute tubular injury.”
> “All six patients had an APOL1 high-risk genotype. Five patients needed dialysis (two of whom died); one partially recovered without dialysis.”

Source: [Wu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7460910/)

<a id="topic-2.2.1.6-7"></a>

### Histologic findings: FSGS, collapsing variant, and interstitial fibrosis

> “There were differences in renal histology, particularly more collapsing variants in those with the risk genotype (P=0.02), although this association was confounded by age.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

> “The presence of 2 APOL1 risk variants (G1/G1, G1/G2, and G2/G2), referred to as high-risk genotype, substantially increases the risk of certain kidney diseases like FSGS, collapsing glomerulopathy (HIV and COVID associated), and severe lupus nephritis.”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
